Preview

Гормон роста - 20 лет применения

https://doi.org/10.14341/probl201157171-79

Аннотация

В 1985 г. на фармацевтическом рынке появился рекомбинантный гормон роста (рГР), синтезируемый методом рекомбинантной ДНК. Данное обстоятельство многократно расширило использование рГР во всем мире, дало мощный толчок интенсивному изучению эффективности терапии рГР, совершенствованию дозирования и методов его введения и, как следствие, - улучшению конечного роста и качества жизни пациентов, расширению показаний для назначения рГР. За 20 лет накоплен солидный опыт применения рГР при широком спектре заболеваний: СТГ-дефиците у детей и взрослых, синдромальной и идиопатической низкорослости, задержке внутриутробного развития, хронической почечной недостаточности, ювенильном идиопатическом артрите, заболеваниях кроветворной системы. Терапия рГР при многих состояниях признана эффективной и безопасной при некоторых заболеваниях, опыт применения еще недостаточен и требуется дальнейшее накопление данных.

Об авторе

E Nagaeva



Список литературы

1. Дедов И.И., Петеркова В.А., Безлепкина О.Б., Нагаева Е.В. Соматотропная недостаточность у взрослых. Атлас. М 2004.

2. Петеркова В.Ф., Фофанова О.В., Тюльпаков А.Н. и др. Национальный консенсус. Диагностика и лечение соматотропной недостаточности у детей. М 2005.

3. Bouillon R., Koledova E., Bezlepkina J. et al. Bone status and fracture prevalenct in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol 2004;89:10:4993-4998.

4. Gibney J., Wallace J.D., Spinks T. et al. The effects of 10 years of recombinant human growth hormone (GH) in adults GH-deficient patients. J Clin Endocrinol Metab 1999;84:8:2596-2602.

5. Svensson J., Stibrant Sunnerhagen K., Jahannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 2003;88:5:2061-2069.

6. Bravenboer N., Holzmann P.J., ter Maaten J.C. et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 2005;20:10:1778-1784.

7. Bex M., Abs R., Maiter D. et al. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002;17:6:1081-1094.

8. Maison P., Griffin S., Nicoue-Beglah M. et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:5:2192-2199.

9. Chrisoulidou A., Beshyah S.A., Rutherford O. et al. Effect of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000;85:10:3762-3769.

10. Shaneyfelt T., Husein R., Bubley G. et al. Hormonal predictors of prostat cancer: a metaanalisis. J Clin Oncol 2000;18:4:847-853.

11. Hankinson S.E., Willet W.C., Colditz G.A. et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.

12. Ma J., Pollak M.N., Giovannucci E. et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF-I) and IGF-binding protein-3. J Natl Cancer Inst 1999;91:7:620-625.

13. Underwood L.E. Report of the conference on usts and possible abuses of biosynthetic human growth hormone. N Engl J Med 1984;311:9:606-608.

14. Lupu F., Terwilliger J.D., Lee K. et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001;229:1:141-162.

15. Cohen P., Weng W., Kappelgaard AM. et al. Multivariate analysis of height from an IGF-1 based GH trial in children with short stature. Adstract OR32-3 presented at the 88th annual meeting of the Endocrine Society. Boston 2006.

16. Dos Santos C., Essioux L., Teinturier C. et al. A common polimorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004;36:7:720-724.

17. Rongen-Westerlaken C., Corel L., van den Broeck J. et al. Reference values for height, height velocity and weight in Turner's syndrome. Acta Pediat 1997;86:9:937-942.

18. Holl R.W., Kunze D., Etzrodt H. et al. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediat 1994;153:1:11-16.

19. Rosenfield R.L., Devine N., Hunold J.J. et al. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005;90:12:6424-6430.

20. Bondy C.A. Care of girls and women with Turner syndrome: a guideline of the Turner syndrome study grope. J Clin Endocrinol Metab 2007;92:1:10-25.

21. Davenport M.L., Crowe D.J., Travers S.H. et al. Growth hormone corrects early growth failure in Turner syndrome: results from the randomaized, controlled, multi-center, "Toddler Turner's study. J Clin Endocrinol Metab 2008;92:4:3363-3369.

22. Van Pareren Y.K., Keizer-Schrama M., Stijnen T. et al. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:3:1119-1125.

23. Bakalov V.K., Cooley M.M., Quon M.J. et al. Impaired insulin secrecion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004;89:7:3516-3520.

24. Sas T.C., de Muinck Keizer-Schrama S.M., Stijnen T. et al. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized doze-response study. Dutch advisory group on growth hormone. J Clin Endocrinol Metab 2000;85:2:769-775.

25. Elder D.A., Roper M.G., Henderson R.C. et al. Kyphosis in a Turner syndrome population. Pediatrics 2002;109:e93.

26. Blethen S.L., Rundle A.C. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative growth study axperience. Horm Res 1996;46:3:113-116.

27. Lowenstein E.J., Kim K.H., Glick S.A. Turner's syndrome in dermatology. J Am Acad Dermatol 2004;50:5:767-776.

28. Sybert V.P. Cardiovascular malformations and complications in Turner syndrome. Pediatrics 1998;101:1:E11.

29. Wollmann H.A. Intrauterin growth restriction: definition and etio­logy. Horm Res 1998;49:Suppl 2:1-6.

30. Петеркова В.А., Фованова О.А., Нагаева Е.В. Эффективность и безопасность применения растворимой формы рекомбинантного гормона роста при лечении низкорослости у детей с задержкой внутриутробного развития. Пробл эндокринол 2005;51:4:27-31.

31. Bannink E., Djurhuus C.B., Christensen T. et al. Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. J Med Econ 2010;13:2:221-227.

32. Sas T.C., de Ridder M.A., Wit J.M. et al. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediat 2010;74:3:172-181.

33. de Zegher F., Ong K.K., van Helvoirt M. et al. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secrecion and associated with a reversible decrease in insuline sensitivity. J Clin Endocrinol Metab 2002;87:1:148-151.

34. Шандин А.Н., Нагаева Е.В., Петеркова В.А., Дедов И.И. Эффективность и безопасность применения рекомбинантного гормона роста у детей с идиопатической низкорослостью. Пробл эндокринол 2010;56:6:14-23.

35. Leschek E.W., Rose S.R., Yanovski J.A. et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopatic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:7:3140-3148.

36. Quigley C.A., Gill A.M., Crowe B.J. et al. Safety of GH treatment in patients with idiopatic short stature. J Clin Endocrinol Metab 2005;90:5188-5196.

37. Crowe B.J., Rekers-Mombard L.T. et al. European Idiopathic Short Stature Group. Effect of growth hormone dose on bone maturation and puberty in children with idiopatic short stature. J Clin Endocrinol Metab 2006;91:1:169-175.

38. Darendeliler F., Ranke M.B., Bakker B. et al. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopatic growth hormone deficiency, Turner syndrome or with idiopatic short stature, and in short children born small for gestational age: analisis of data from KIGS. Horm Res 2005;63:40-47.

39. Kemp S.F., Kuntze J., Attie K.M. et al. Efficacy and safety results of long-term growth hormone treatment of idiopatic short stature. J Clin Endocrinol Metab 2005;90:9:5247-5253.

40. Furth S.L. Growth and nutrition in children with chronic kidney disease. Adv. Chronic Kidney Dis 2005;12:4:366-371.

41. Haffner D., Schaefer F., Girard J. et al. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest 1994;93:3:1163-1171.

42. Tonshoff B., Cronin M.J., Reichert M. et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with renal failure: correlation with GH insensitivity. J Clin Endocrinol Metab 1997;82:1007-10013.

43. Rabkin R., Sun D.F., Chen Y. et al. Growth hormone resistence in uremia, a role for impaired JAK/STAT signaling. Pediatr Nephrol 2005;20:3:313-318.

44. Tonhoff B., Blum W.F., Winger A.M. et al. Serum insulin-like factors (IGFs) and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: relationship to hight and glomerular filtration rate. J Clin Endocrinol Metab 1995;80:2684-2691.

45. Vimalachandra D., Hodson E.M., Willis N.S. et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2001;3:CD003264.

46. Петеркова В.А., Нагаева Е.В., Кварацхелия М.В. Гормон роста в лечении детей с хронической почечной недостаточностью. Методическое пособие для врачей. М 2008.

47. Сrompton C.H. Long-term recombinant human growth hormone use in Australian children with renal disease. Nephrol 2004;9:5:325-330.

48. Fine R.N., Ho M., Tejani A. et al. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediat 2003;142:5: 345-539.

49. Guest G., Berard E., Crosnier H. et al. Effects of growth hormone in short children after renal transplantation. Pediatr Nephrol 1998;12:6:437-446.

50. Berchtold S., Ripperger P., Hafner R. et al. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 2003;143:4:512-519.

51. Gonneli S., Cepollaro C., Montomoli M. et al. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Clin Endocrinol (Oxford) 1997;46:1:55-61.

52. Cittadini A., Isgaard J., Manti M.G. et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41:12:2154-2163.

53. Demers C., McKelvie R.S. Growth hormone therapy in heart failure: where we are now? Congest Heart Fail 2003;9:2:84-90.

54. Hadzonic A., Nakas-Icindic E., Kucukalic-Selimovic E. et al. Growth hormone (GH): usage and abuse. Bosn J Basic Med Sci 2004;4:4:66-70.


Для цитирования:


. Гормон роста - 20 лет применения. Проблемы Эндокринологии. 2011;57(1):71-79. https://doi.org/10.14341/probl201157171-79

For citation:


Nagaeva E.V. Growth hormone - 20 years of clinical practice. Problems of Endocrinology. 2011;57(1):71-79. (In Russ.) https://doi.org/10.14341/probl201157171-79

Просмотров: 22


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)